November 25, 2024 03:55 (IST)

Make this your homepage

Health

Mahayuti routs MVA in Maharashtra, INDIA retains Jharkhand; Priyanka's triumphant poll debut | How can Mahayuti win over 200 seats? Sanjay Raut cries foul over Maharashtra mandate | 'Third World War has begun:' Ex-Ukraine military commander-in-chief Valery Zaluzhny | UK-India Free Trade Agreement negotiations to resume in early 2024 | UK can arrest Benjamin Netanyahu if he visits country based on ICC warrant | Centre to send over 10,000 additional soldiers to violence-hit Manipur amid fresh violence | Chhattisgarh: 10 Maoists killed during encounter with security forces in Sukma | Baba Siddique murder case: Arrested Akashdeep Gill used a labourer's hotspot to evade tracking, say police | Donald Trump picks 'smart and tough' Pam Bondi as new US Attorney General after Matt Gaetz withdraws | Canadian government denies media report that claims PM Modi knew of Khalistani leader Nijjar's killing

India | COVID vaccines

Image Credit: Unsplash

In a big boost, Covaxin, Covishield get full market authorisation

India Blooms News Service | @indiablooms | Sep 19, 2024, at 01:28 am

#India #COVID19 #Covishield #Covaxin #DGCI #Vaccination

COVID-19, an expert panel of the central drug authority on Wednesday cleared the country's two indigenous vaccines-Covaxin and Covishield-for full use.

New Delhi/IBNS: In a big boost to India's fight against COVID-19, an expert panel of the central drug authority on Wednesday cleared the country's two indigenous vaccines-Covaxin and Covishield-for full use.

The development comes a year after these vaccines' administration on an emergency-use basis started in India.

With this move, the vaccines are expected to be widely available at hospitals and clinics soon, which are registered with the government portal CoWIN.

This will also aid in booster doses, which Prime Minister Narendra Modi announced last month to be administered on health and frontline workers and adults above 60 years of age, as precautionary third doses.

The recommendation by the expert panel of the Central Drugs Standard Control Organisation (CDSCO) has been sent to the top drug regulator DGCI.

"SEC of CDSCO has recommended for the upgrade of Covishield and Covaxin status from restricted use in emergency situations to grant of new drug permission with conditions in the adult population, DCGI will evaluate the recommendations and give its decision," the regulatory body tweeted.

SEC of CDSCO has recommended for upgrade of covishield and covaxin status from restricted use in emergency situations to grant of new drug permission with conditions In adult population ,DCGI will evaluate the recommendations and give its decision.
— CDSCO_INDIA_INFO (@CDSCO_INDIA_INF) January 19, 2022

India’s COVID-19 vaccination coverage has crossed 159.54 Crore on Wednesday, the Union Health Ministery stated.

More than 62 lakh vaccine doses have been administered till 7 pm.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.